Welcome to our dedicated page for Evogene news (Ticker: EVGN), a resource for investors and traders seeking the latest updates and insights on Evogene stock.
Evogene Ltd. (EVGN) is a computational biology and chemistry company that regularly publishes news about its AI‑driven platforms, collaborations and corporate developments. The EVGN news feed on Stock Titan aggregates company press releases and related coverage so readers can follow how Evogene applies big data and artificial intelligence to life‑science product discovery in pharmaceuticals and agriculture.
Recent announcements highlight Evogene’s focus on ChemPass AI, its generative AI tech‑engine for small‑molecule design and optimization. News items include the completion of a generative AI foundation model for small‑molecule design developed with Google Cloud, as well as updates on how ChemPass AI is being positioned as the core engine for the company’s pharma and agricultural activities.
Evogene’s news also covers scientific collaborations, such as agreements with Unravel Biosciences to design small‑molecule therapeutics for demyelinating diseases and with a Tel Aviv University research group to develop small molecules targeting metabolite self‑assembly in metabolic diseases. In agriculture, readers can find updates related to subsidiaries like Casterra Ag, including partnerships to advance mechanized castor farming for bio‑based industries.
In addition, the EVGN news stream features financial and corporate communications, including quarterly results, conference call schedules, investor conference presentations, restructuring steps and transactions such as the sale of most of Lavie Bio’s activity and the MicroBoost AI for Ag platform to ICL. Investors and observers can use this page to monitor how Evogene’s strategy, partnerships and technology platforms evolve over time.
Evogene (NASDAQ: EVGN) subsidiary Casterra reported successful commercial field trials across 74 hectares in Bahia, Brazil, showing mechanized, low-input castor farming can be economically viable for castor oil feedstock. Trials included 64 hectares rainfed, 10 hectares irrigated, and recorded 382 mm rainfall.
Casterra plans a 2026 push via a local subsidiary, strategic partnerships with castor oil producers, and expanded trials across multiple Brazilian states to support castor as a scalable biofuel feedstock.
Evogene (NASDAQ: EVGN) will present pharma discovery achievements at BIO-Europe Spring 2026 in Lisbon, March 23–25, 2026. Evogene delegates Dr. Gabi Tarcic and Dr. Olga Nissan will deliver an oral presentation on March 24, 2026, 15:30 WET and are available for one-on-one meetings.
The presentation will highlight AI-driven small-molecule discovery and the company’s ChemPass AI™ platform enabling collaborative drug discovery with pharma and biotech partners.
Evogene (NASDAQ: EVGN) reported fourth-quarter and full-year 2025 results and outlined a strategic refocus on its proprietary ChemPass AI™ small‑molecule engine for pharma and agriculture. 2025 highlights include operating expenses reduced to ~$13.8M, consolidated cash of ~$13.0M, 2025 revenue of ~$3.9M, and a $6.4M gain from the Lavie Bio asset sale.
The company recorded a 2025 operating loss of ~$14.0M and net loss of ~$7.8M, implemented divestitures and restructurings, recognized a $2.2M inventory impairment at Casterra, and secured ~ $3.4M gross proceeds from a February 2026 warrant exercise inducement.
Evogene (Nasdaq: EVGN) outlined a 2025 strategic transformation to focus on its proprietary ChemPass AI™ engine and two markets: human health and agriculture. The company divested non-core assets, resized the organization, and said ChemPass AI™ leverages a 38‑billion‑molecule foundation model and partnerships including Google Cloud, Bayer, and Corteva.
Evogene reported partnered drug discovery progress, four disclosed collaborations, AgPlenus agricultural programs, and completed divestments of Lavie Bio and a license of Biomica's BMC128.
Evogene (NASDAQ: EVGN) will release its fourth quarter and full year 2025 financial results on Thursday, March 5, 2026. Management will discuss results in a Zoom conference call the same day at 9:00 AM ET (4:00 PM Israel time).
Investors must register in advance to attend and the full webcast will be posted on the company's website a few days after the call. Registration link: https://www.veidan-conferencing.com/evogene.
Evogene (Nasdaq: EVGN) announced a collaboration with Dr. Mark Adams' group at Queensland University of Technology on Feb 17, 2026 to accelerate AI-driven discovery of small-molecule inhibitors targeting a newly identified enzymatic detoxification pathway that drives Cisplatin resistance in non-small cell lung cancer (NSCLC).
The partnership combines Evogene's ChemPass AI™ generative design platform with QUT's biological insights to generate and iteratively refine drug-like leads aimed at restoring chemotherapy and targeted-therapy sensitivity.
Evogene (Nasdaq: EVGN), Systasy Bioscience and LMU University Hospital Munich announced a collaborative program on Feb. 11, 2026 to develop novel therapies for neutrophil-driven hyper-inflammatory diseases, including IBD. The effort is supported by a pan-European EUREKA grant and includes participation from the Weizmann Institute.
Evogene will lead small-molecule discovery using its ChemPass AI™; Systasy will apply its PathwayProfiler DNA barcoding assays; LMU will validate leads in human stem cell–derived neutrophil models and advance biomarkers and translational plans.
Evogene (Nasdaq: EVGN) entered a warrant inducement agreement with an existing institutional investor to generate approximately $3.4 million of gross proceeds. The investor will immediately exercise August 2024 Series A and B warrants at $1.00 per share.
In return, the investor receives privately placed Series A-1 and B-1 warrants to buy up to 2,538,462 shares each at an exercise price of $1.25; A-1 expires in five years and B-1 in 18 months. Closing is expected on or about February 11, 2026, subject to customary conditions.
Evogene (NASDAQ: EVGN) announced on February 10, 2026 an expanded collaboration with Google Cloud to integrate advanced AI agents into its ChemPass AI™ platform using Google Cloud Vertex AI. The phase aims to accelerate and scale small-molecule discovery, shorten design–make–test–analyze cycles, and enable parallel molecular exploration.
The move follows a prior October 2024 milestone that built a generative AI foundation model now core to ChemPass AI™. Evogene said the partnership could broaden offerings, improve speed and cost structure, and make some tools available via Google Cloud Marketplace.
Evogene (NASDAQ: EVGN) appointed Prof. John J. Irwin (UCSF) and Prof. Dan T. Major (Bar-Ilan) to its Scientific Advisory Board on February 9, 2026.
The appointments are intended to strengthen scientific leadership for ChemPass AI™, Evogene's proprietary generative AI engine for small-molecule discovery across pharmaceutical and ag-chemical programs.